________________________________________________________________________________________________________________________________

(C) University College Dublin 2011 - Walter KolchSystems Biology in Search of Good Questions

December 2011. Walter Kolch, Director, Systems Biology Ireland & Conway Institute at University College Dublin describes SBI’s approach to systems biology in an exclusive interview with B2Bioworld. What is unique compared to Institutes at Seattle, Tokyo, Singapore, Luxembourg, or other where. What is the role of theory to guide experiments? Is there a non-trivial meaning of “perturbation” experiments? Which diseases are targeted, and which strategies are followed to answer those questions which AstraZeneca, Hewlett Packard, Pfizer, Servier, and other pharma and IT partners are eager to know beforehand.

If you like to read this article, you can purchase it now

Please notice, when purchasing articles you agree to B2Bioworld's Terms and Conditions

Read Now - Please select your license (Prices incl. 7% VAT)

Article free of advertisement - 5 pages
- Includes explanation of post-translational modification, organisation of scientific programme

Full Company License enquire here

Back to section

Related Editorial Articles

Systems Biology Applied
Rudi Balling, Director Luxembourg Centre for Systems Biomedicine on the Need of Systems Theory Thinking in Using Technologies and Pitfalls of Key Concepts

Patient-centered Precision Care
Michael Christman, President of Coriell Institute about turning research on human genotyping into healthcare routine

Drug Testing with Embryonic Stem Cells
- Towards standards for assays

Leroy Hood: Thinking Further about Stem Cells

Stem Cells – Failings and Deliveries
Hugh Ilyine, former longtime COO of Stem Cell Sciences looks at clinical trials, reimbursement prospects, and interest of venture capital

Stem Cell Research Now and in the Future
Patrick Vallance, today President Pharmaceuticals, R&D of GlaxoSmithKline on company strategy and the the role of cancer stem cells

Doing our business a little bit differently than the others in industry
Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk on stem cell approaches to diabetes

Stem Cells: a discovery tool and a potential therapeutic modality
Jonathan Knowles, Former Member of the Roche Executive Committee and Head of Group Research Leveraging different methods and technologies – clarifying the concept of personalised medicine

Pfizer Regenerative Medicine (Neusentis): It really started last year…
Ruth McKernan, global CSO of Pfizer’s Regenerative Medicine Unit (today Neusentis) addresses basic and practical issues in pharmaceutical research on stem cells

Metrics for Disease, Health, and Wellness
A systems look at DNA sequencing for personalized medicine by Leroy Hood, President Institute for Systems Biology, Seattle

Plant Genetic Engineering:”It’s not as simple as Yes or No!”
Nobel Prize winner Christiane Nüsslein-Volhard Warns of GMO-populism and researchers not standing up. Exclusive interview for readers of B2Bioworld